153 related articles for article (PubMed ID: 23538188)
1. The cost-effectiveness of a novel SIAscopic diagnostic aid for the management of pigmented skin lesions in primary care: a decision-analytic model.
Wilson EC; Emery JD; Kinmonth AL; Prevost AT; Morris HC; Humphrys E; Hall PN; Burrows N; Bradshaw L; Walls J; Norris P; Johnson M; Walter FM
Value Health; 2013; 16(2):356-66. PubMed ID: 23538188
[TBL] [Abstract][Full Text] [Related]
2. Protocol for the MoleMate UK Trial: a randomised controlled trial of the MoleMate system in the management of pigmented skin lesions in primary care [ISRCTN 79932379].
Walter FM; Morris HC; Humphrys E; Hall PN; Kinmonth AL; Prevost AT; Wilson EC; Burrows N; Norris P; Johnson M; Emery J
BMC Fam Pract; 2010 May; 11():36. PubMed ID: 20459846
[TBL] [Abstract][Full Text] [Related]
3. Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial.
Walter FM; Morris HC; Humphrys E; Hall PN; Prevost AT; Burrows N; Bradshaw L; Wilson EC; Norris P; Walls J; Johnson M; Kinmonth AL; Emery JD
BMJ; 2012 Jul; 345():e4110. PubMed ID: 22763392
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of SIAscopy for pigmented skin lesions encountered in primary care: development and validation of a new diagnostic algorithm.
Emery JD; Hunter J; Hall PN; Watson AJ; Moncrieff M; Walter FM
BMC Dermatol; 2010 Sep; 10():9. PubMed ID: 20868511
[TBL] [Abstract][Full Text] [Related]
5. VivaScope® 1500 and 3000 systems for detecting and monitoring skin lesions: a systematic review and economic evaluation.
Edwards SJ; Mavranezouli I; Osei-Assibey G; Marceniuk G; Wakefield V; Karner C
Health Technol Assess; 2016 Jul; 20(58):1-260. PubMed ID: 27483991
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years.
Gordon LG; Brynes J; Baade PD; Neale RE; Whiteman DC; Youl PH; Aitken JF; Janda M
Value Health; 2017 Apr; 20(4):593-601. PubMed ID: 28408001
[TBL] [Abstract][Full Text] [Related]
7. A Modeling Study of the Cost-Effectiveness of a Risk-Stratified Surveillance Program for Melanoma in the United Kingdom.
Wilson ECF; Usher-Smith JA; Emery J; Corrie P; Walter FM
Value Health; 2018 Jun; 21(6):658-668. PubMed ID: 29909870
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and economic evaluation of exercise referral schemes in primary care: a short report.
Campbell F; Holmes M; Everson-Hock E; Davis S; Buckley Woods H; Anokye N; Tappenden P; Kaltenthaler E
Health Technol Assess; 2015 Jul; 19(60):1-110. PubMed ID: 26222987
[TBL] [Abstract][Full Text] [Related]
9. Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis.
Westwood M; Ramaekers B; Lang S; Grimm S; Deshpande S; de Kock S; Armstrong N; Joore M; Kleijnen J
Health Technol Assess; 2018 Aug; 22(44):1-264. PubMed ID: 30165935
[TBL] [Abstract][Full Text] [Related]
10. The Cost-Effectiveness of Bimodal Stimulation Compared to Unilateral and Bilateral Cochlear Implant Use in Adults with Bilateral Severe to Profound Deafness.
Theriou C; Fielden CA; Kitterick PT
Ear Hear; 2019; 40(6):1425-1436. PubMed ID: 30998548
[TBL] [Abstract][Full Text] [Related]
11. Visual screening for malignant melanoma: a cost-effectiveness analysis.
Losina E; Walensky RP; Geller A; Beddingfield FC; Wolf LL; Gilchrest BA; Freedberg KA
Arch Dermatol; 2007 Jan; 143(1):21-8. PubMed ID: 17224538
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the MoleMate training program for assessment of suspicious pigmented lesions in primary care.
Wood A; Morris H; Emery J; Hall PN; Cotton S; Prevost AT; Walter FM
Inform Prim Care; 2008; 16(1):41-50. PubMed ID: 18534076
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of exercise referral schemes: a systematic review and economic evaluation.
Pavey TG; Anokye N; Taylor AH; Trueman P; Moxham T; Fox KR; Hillsdon M; Green C; Campbell JL; Foster C; Mutrie N; Searle J; Taylor RS
Health Technol Assess; 2011 Dec; 15(44):i-xii, 1-254. PubMed ID: 22182828
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of exercise referral schemes.
Anokye NK; Trueman P; Green C; Pavey TG; Hillsdon M; Taylor RS
BMC Public Health; 2011 Dec; 11():954. PubMed ID: 22200193
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of a national exercise referral programme for primary care patients in Wales: results of a randomised controlled trial.
Edwards RT; Linck P; Hounsome N; Raisanen L; Williams N; Moore L; Murphy S
BMC Public Health; 2013 Oct; 13():1021. PubMed ID: 24164697
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
Value Health; 2010; 13(1):55-60. PubMed ID: 19804431
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial.
Pollard DJ; Brennan A; Dixon S; Waugh N; Elliott J; Heller S; Lee E; Campbell M; Basarir H; White D;
BMJ Open; 2018 Apr; 8(4):e016766. PubMed ID: 29627802
[TBL] [Abstract][Full Text] [Related]
18. Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary care.
Lambe T; Adab P; Jordan RE; Sitch A; Enocson A; Jolly K; Marsh J; Riley R; Miller M; Cooper BG; Turner AM; Ayres JG; Stockley R; Greenfield S; Siebert S; Daley A; Cheng KK; Fitzmaurice D; Jowett S
Thorax; 2019 Aug; 74(8):730-739. PubMed ID: 31285359
[TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.
Elliott RA; Tanajewski L; Gkountouras G; Avery AJ; Barber N; Mehta R; Boyd MJ; Latif A; Chuter A; Waring J
Pharmacoeconomics; 2017 Dec; 35(12):1237-1255. PubMed ID: 28776320
[TBL] [Abstract][Full Text] [Related]
20. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
